<oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><id>3166</id>
	<dc:title xml:lang="en-US">Neuroinflammation: 2021 update</dc:title>
	<dc:creator>Lassmann, Hans</dc:creator>
	<dc:subject xml:lang="en-US">Brain inflammation</dc:subject>
	<dc:subject xml:lang="en-US">COVID-19</dc:subject>
	<dc:subject xml:lang="en-US">Multiple sclerosis</dc:subject>
	<dc:subject xml:lang="en-US">Alzheimer's disease</dc:subject>
	<dc:subject xml:lang="en-US">MOGAD</dc:subject>
	<dc:description xml:lang="en-US">Key requirements for the validity of a neuropathological study are the inclusion of large numbers of biopsy or autopsy cases and proper controls, the rigorous classification of the basic neuropathology and the selection of the most suitable technologies for investigation. Whether the studies are performed with the fanciest, new, and state of the art technology or with rather conventional methodology is of minor importance. Fol-lowing these criteria, a spectrum of neuropathological studies has been published in 2020, which provides new insights on important questions related to neurological disease. They include the pathological substrate of brain disease in COVID-19 infected patients, the nature of the adaptive and innate inflammatory response, or the type and mechanisms of tissue injury and repair in multiple sclerosis, and diagnostically relevant or mechanistic new insights into antibody-mediated diseases of the central nervous system. Other studies de-scribe in detail the dynamic changes of brain inflammation in patients with trisomy 21 as a disease model for Alzheimerâ€™s disease, or the presence and consequences of vascular comorbidities in a chronic inflammatory disease, such as multiple sclerosis. All these contributions have provided important, highly relevant clues for basic and translational neuroscience.</dc:description>
	<dc:publisher xml:lang="en-US">Prof. Dr. Werner Paulus, University of Muenster, Institute of Neuropathology</dc:publisher>
	<dc:date>2021-01-12</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en-US">Review</dc:type>
	<dc:format>text/html</dc:format>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://www.uni-muenster.de/Ejournals/index.php/fnp/article/view/3166</dc:identifier>
	<dc:identifier>10.17879/freeneuropathology-2021-3166</dc:identifier>
	<dc:source xml:lang="de-DE">Free Neuropathology; Bd. 2 (2021); 1</dc:source>
	<dc:source xml:lang="en-US">Free Neuropathology; Vol. 2 (2021); 1</dc:source>
	<dc:source>2699-4445</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://www.uni-muenster.de/Ejournals/index.php/fnp/article/view/3166/3147</dc:relation>
	<dc:relation>https://www.uni-muenster.de/Ejournals/index.php/fnp/article/view/3166/3146</dc:relation>
	<dc:relation>urn:nbn:de:hbz:6:3-freeneuropathology-2021-31469</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2021 Hans Lassmann</dc:rights>
</oai_dc:dc>